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Interleukin (IL)-33, an IL-1 family member, acts as an extracellular cytokine by binding its cognate recep-
tor, ST2. IL-33 is also a chromatin-binding transcriptional regulator highly expressed in the nuclei of
endothelial cells. However, the function of IL-33 as a nuclear factor is poorly deﬁned. Here, we show that
IL-33 is a novel transcriptional regulator of the p65 subunit of the NF-jB complex and is involved in
endothelial cell activation. Quantitative reverse transcriptase PCR and Western blot analyses indicated
that IL-33 mediates the expression of intercellular adhesion molecule (ICAM)-1 and vascular cell adhe-
sion molecule (VCAM)-1 in endothelial cells basally and in response to tumor necrosis factor-a-treat-
ment. IL-33-induced ICAM-1/VCAM-1 expression was dependent on the regulatory effect of IL-33 on
the nuclear factor (NF)-jB pathway; NF-jB p65 expression was enhanced by IL-33 overexpression and,
conversely, reduced by IL-33 knockdown. Moreover, NF-jB p65 promoter activity and chromatin immu-
noprecipitation analysis revealed that IL-33 binds to the p65 promoter region in the nucleus. Our data
provide the ﬁrst evidence that IL-33 in the nucleus of endothelial cells participates in inﬂammatory reac-
tions as a transcriptional regulator of NF-jB p65.
 2012 Elsevier Inc. Open access under CC BY-NC-ND license.1. Introduction
Inﬂammation is a typical response to infectious agents or tissue
injury that involves activation of vascular endothelial cells and local
recruitment of circulating leukocytes from the blood to the in-
ﬂamed site [1]. Endothelial cell activation induces the expression
of cell adhesion molecules, such as intercellular adhesion molecule
(ICAM)-1 and vascular cell adhesionmolecule (VCAM)-1, that assist
in the recruitment of leukocytes during the inﬂammatory process.
Binding of interleukin-1 (IL-1) family members to their receptors
leads to the induction of inﬂammatory genes, such as cytokines,
chemokines, and cell adhesion molecules, via nuclear factor-jB
(NF-jB) and the modulation of inﬂammatory responses [2,3].
IL-33, also known as the nuclear factor from high endothelial
venules (NF-HEVs), is a member of the IL-1 cytokine family that in-
cludes IL-1 and IL-18. IL-33 is expressed in ﬁbroblasts, epithelium,Y-NC-ND license. 
P, chromatin immunoprecip-
-mobility group protein B1;
AM-1, intercellular adhesion
RT-PCR, quantitative reverse
AM-1, vascular cell adhesion
).and endothelium [4,5]. IL-33 is synthesized as an approximately
30-kDa precursor and in response to tissue injury, the full length
form of IL-33 is thought to be released as a cytokine [6]. Cytokine
IL-33 binds to a heterodimer of ST2 receptor and IL-1R accessory
protein (IL-1RAcP) on inﬂammatory cells, such as mast cells, T lym-
phocytes, eosinophils, basophils, and neutrophils and modulates
inﬂammatory diseases like sepsis, asthma, anaphylaxis, and arthri-
tis [7].
The 30-kDa precursor form of IL-33, like IL-1a and high motility
group box 1 (HMGB1), likely acts as an intracellular protein that
exerts biological activities in the nucleus as IL-33 is constitutively
expressed in the nucleus even in the absence of proinﬂammatory
stimuli [8]. IL-33 is expressed in the nuclei of MECA 79-positive
HEVs in tonsils, Peyer’s patches, and lymph nodes as well as in in-
ﬂamed tissues in inﬂammatory conditions, such as Crohn’s disease,
rheumatoid arthritis, and atherosclerosis [4,9]. The IL-33N-termi-
nal homeodomain-like helix-turn-helix motif is responsible for
nuclear targeting and chromatin binding. This short chromatin-
binding motif (CBM) of IL-33 associates with the acidic pocket
formed by H2A and H2B [10]. Despite the fact that IL-33 acts as a
nuclear factor and a cytokine, neither the transcriptional targets
nor the pathophysiological role of nuclear IL-33 in endothelial cells
have been examined. Our results demonstrate a nuclear role for
IL-33 in the transcriptional regulation of NF-jB p65 through which
306 Y.-S. Choi et al. / Biochemical and Biophysical Research Communications 421 (2012) 305–311IL-33 induces the expression of cell adhesion molecules (ICAM-1
and VCAM-1). Nuclear IL-33 exerts its biological effect in a recep-
tor-independent manner.
2. Materials and methods
2.1. Cell culture
Human umbilical vein endothelial cells (HUVECs) were isolated
fromhumanumbilical cord veins by collagenase treatment andused
at passages 2–7. Cells were grown in M199 medium (Invitrogen,
Carlsbad,CA) supplementedwith20% fetal bovineserum,1%penicil-
lin/streptomycin, 3 ng/ml basic ﬁbroblast growth factor (R&D Sys-
tems Minneapolis, MN), and 5 U/ml heparin (Sigma, St. Louis, MO)
at 37 C in a humidiﬁed 95–5% (v/v) mixture of air and CO2.
2.2. Quantitative real-time reverse transcription PCR (qRT-PCR)
Real-time PCR was performed with SYBR Green (Invitrogen) in a
Bio-Rad real-time PCR detection system. The primers used for qRT-
PCR were as follows: IL-33, 50-CCATTACTTTTGCTTTGGAGGA-30 and
50-CCATTACTTTTGCTTTGGAGGA-30; ICAM-1, 50-GAAGTGGTGGGG-
GAGACATA-30 and 50-CAAGGGTTGGGGTCAGTAGA-30; VCAM-1, 50-
AAAAGCGGAGACAGGAGACA-30 and 50-GCAAAATAGAGCACGA-
GAAGC-30; p65, 50-ACTGTTCCCCCTCATCTTCC-30 and 50-TGGTCCTG
TGTAGCCATTGA-30; ST2, 50-AAGGAGTTTGCCTACGAGCA-30 and 50-
CCACTTGATGGTCCCCTGTA-30; GAPDH, 50-ACCCAGAAGACTGTG-
GATGG-30 and 50-TCTAGACGGCAGGTCAGGTC-30.
2.3. Transient transfection and luciferase assays
Total RNAwas isolated fromHUVECs and cDNAwas synthesized
using M-MLV reverse transcriptase (Promega, Madison, WI). IL-33
cDNA (817 bp) was ampliﬁed from HUVEC cDNA and subcloned
into pFLAG-CMV2. ICAM-1 (1350 bp), VCAM-1 (1716 bp), and
4x-jB luciferase reporter constructs were used as previously de-
scribed [11]. The NF-jB p65 promoter was ampliﬁed from a BAC
clone (RP11–856B14) and subcloned into pGL3-Basic (Promega).
HUVECs were transfected with expression plasmid, reporter con-
struct, and pRL-CMV for normalization using Lipofectamine as per
the manufacturer’s instructions (Invitrogen). After 24 h, HUVECs
were lysed with passive lysis buffer and luciferase activity was
measured using the Dual-Luciferase Reporter Assay System
(Promega).
2.4. Transfection with small interfering (si)RNA
HUVECs were transfected with control siRNA and IL-33 siRNA
(Dharmacon, Lafayette, CO) using Lipofectamine for 3 h. Cells were
assayed 48 h after transfection. For IL-33, siRNAs were used: 50-
GCACAUACAAUGAUCAAUC-30. To silence ST2 expression, a ST2 siR-
NA sequence (Dharmacon; 50-CGAAAGAGCAGGCGGCACAUU-30)
was used.
2.5. Monocyte adhesion assays
HUVECs were transfected with siRNA in 60-mm plates. After
24 h, HUVECs were re-plated in 96-well plates at 2  104 cells/well
overnight. THP-1 cells were labeled with 5 lM calcein-AM (Sigma)
and incubated at 37 C for 30 min. Calcein-AM-labeled cells were
co-cultured with conﬂuent endothelial cells for 1 h. The cells were
washed with PBS to remove unbound cells. Fluorescence intensi-
ties were measured with a FLUOstar Omega (BGM LABTECH, Offen-
burg, Germany) with excitation and emission wavelengths set to
494 and 517 nm, respectively.2.6. Western blot analysis
HUVECs were washed with cold PBS, harvested in buffer (0.1%
NP-40, 10 nM NaCl, 5 mM MgCl2, 10 nM NaH2PO4 [pH 7.4],
65 mM sodium orthovanadate), and centrifuged at 1200g for
15 min. After centrifugation, nuclei were pelleted and suspended
in nuclear buffer (1 mM EDTA, 3.5% SDS, 10% glycerol, and
70 mM Tris–Cl), as described previously [8]. The proteins were sep-
arated by SDS–PAGE. Immunoblotting was performed with anti-
bodies to IL-33 (R&D Systems), ICAM-1, VCAM-1, p65, b-actin
(Santa Cruz Biotechnology, Santa Cruz, CA), and histone H3 (Milli-
pore, Billerica, MA).
2.7. Chromatin immunoprecipitation (ChIP) assay
ChIP was performed using a ChIP assay kit (Millipore) according
to the manufacturer’s instructions. HUVECs were transfected with
a FLAG-tagged IL-33 expression vector for 48 h. FLAG-speciﬁc
monoclonal antibodies (Sigma) or mouse control IgG (Santa Cruz
Biotechnology) were added to precleared chromatin and incubated
overnight at 4 C. The DNA was ampliﬁed with primers speciﬁc to
the p65 promoter (50-GCACTGTGGGGTCACATGACAGAA-30 and 50-
AGGGCTCGTCCCTCTCCAGCTAAA-30) or with negative control
primers (50-GATTGAAGCCCTCCAAAAGC-30 and 50-ACCATCAGGA-
CAGGGGAA AA-30).
2.8. Immunocytochemistry
HUVECs were ﬁxed in 3.7% formaldehyde for 10 min and per-
meabilized with 0.1% Triton X-100 in PBS. Cells were blocked with
1% BSA (Millipore) for 1 h at room temperature. The cells were
washed with PBS, labeled with anti-p65 antibody (Santa Cruz Bio-
technology) for 2 h at room temperature, rinsed in PBS, and incu-
bated with AlexaFluor-488 for 60 min at room temperature.
Samples were examined with a ﬂuorescence microscope (Zeiss,
400).
2.9. Statistical analysis
Data were analyzed with Student’s t-tests and expressed as
means ± standard deviation (SD). All experiments were performed
at least three times and representative results are shown.3. Results
3.1. IL-33 regulates ICAM-1 and VCAM-1 expression in resting
endothelial cells
Cell adhesion molecules, including ICAM-1 and VCAM-1, control
cell integrity under physiological condition and regulate inﬂamma-
tion under pathological conditions [12]. Endothelial cells of HEVs
in healthy and inﬂamed tissues express cell adhesion molecules,
such as ICAM-1 and VCAM-1, as well as IL-33 [13]. We examined
the interplay between IL-33 and speciﬁc cell adhesion molecules.
Exposure of HUVECs to IL-33-targeting siRNA decreased the mRNA
and protein levels of ICAM-1 and VCAM-1 according to qRT-PCR
(Fig. 1A) and Western blot analyses (Fig. 1B), respectively. Con-
versely, ectopic expression of IL-33 in HUVECs increased ICAM-1
and VCAM-1 at both the mRNA and protein levels (Fig. 1C and
D). In addition, ICAM-1 and VCAM-1 promoter activities were
reduced by exposure of HUVECs to IL-33 siRNA and elevated in
response to IL-33 (Fig. 1E and F).
IL-33 as a cytokine upregulates ICAM-1 and VCAM-1 via inter-
actions with ST2 receptor in ST2-positive cells [14]. To exclude
the possibility that the upregulation of ICAM-1/VCAM-1 in our
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Fig. 1. IL-33 regulates ICAM-1 and VCAM-1 expression in HUVECs. (A and B) HUVECs were transfected with control siRNA or IL-33 siRNA for 48 h. (C and D) HUVECs were
transfected with mock or IL-33 constructs for 48 h. (A and C) RNA levels of ICAM-1 and VCAM-1 were quantiﬁed by qRT-PCR and normalized to GAPDH levels. (B and D)
Nuclear and cytoplasmic extracts were prepared and protein expression was assessed by Western blot analysis with the indicated antibodies. ⁄⁄⁄P < 0.001 versus control cells.
(E) HUVECs were transfected with control siRNA or IL-33 siRNA for 24 h, followed by transfection with ICAM-1 or VCAM-1 reporter constructs for 24 h. (F) HUVECs were co-
transfected with two reporter constructs and either mock or IL-33 expression plasmids for 24 h. Fireﬂy luciferase activity from ICAM-1 or VCAM-1 reporter constructs was
measured. Transfection efﬁciency was normalized to Renilla luciferase activity from co-transfected pRL-CMV. ⁄P < 0.05, ⁄⁄P < 0.01, and ⁄⁄⁄P < 0.001 versus control vector for
ICAM-1 promoter activity. #P < 0.05 and ###P < 0.001 versus control vector for VCAM-1 promoter activity.
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33, we knocked down ST2 receptor expression using siRNA prior
to IL-33 overexpression (Fig. 2A). ICAM-1 and VCAM-1 were still
upregulated in ST2-silenced HUVECs (Fig. 2B and C). Thus, regula-
tion of ICAM-1 and VCAM-1 by IL-33 is due to its intracellular func-
tions rather than a receptor-mediated effect. These data
demonstrate that nuclear-localized IL-33 mediated ICAM-1 and
VCAM-1 expression in resting endothelial cells.3.2. IL-33 regulates ICAM-1 and VCAM-1 expression in TNF-a-
activated endothelial cells
Inﬂammatory mediators, including TNF-a and LPS, induce
expression of cell adhesion molecules and modulate inﬂammatory
reactions [2]. Given that IL-33 acts in a ﬁrst wave of the inﬂamma-
tory response, nuclear IL-33 in endothelial cells may respond to
inﬂammatory mediators to increase endothelial VCAM-1/ICAM-1expression. Knockdown of IL-33 by siRNA attenuated TNF-a-in-
duced ICAM-1 and VCAM-1 expression at both the mRNA and pro-
tein levels (Fig. 3A and B). Moreover, the VCAM-1/ICAM-1
promoter activity induced by TNF-a was attenuated in IL-33 siR-
NA-treated HUVECs compared with control cells (Fig. 3C and D).
These data demonstrate that, in HUVECs, nuclear IL-33 can regu-
late inﬂammatory mediator-induced ICAM-1 and VCAM-1 expres-
sion as well as their basal expression levels.3.3. Silencing IL-33 in endothelial cells inhibits monocyte adhesion
During inﬂammation, LFA1/VLA1-expressing leukocytes are re-
cruited to the inﬂamed tissue through interactions with ICAM-1/
VCAM-1-expressing endothelial cells [15,16]. To conﬁrm the bio-
logical function of IL-33-mediated ICAM-1/VCAM-1 expression in
HUVECs, we investigated the extent of THP-1 monocyte adhesion
on IL-33-silenced HUVECs. Knocking down IL-33 in both resting
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decrease in the ability of THP-1 monocytes to adhere compared
with control siRNA-treated endothelial cells (Fig. 3E). These data
suggest that cell adhesion molecule expression induced by IL-33
controls monocyte adhesion in resting and TNF-a-activated
HUVECs.
3.4. IL-33 modulates the NF-jB pathway in endothelial cells
NF-jB-dependent pathways contribute to cell adhesion mole-
cule expression to regulate inﬂammatory responses [2]. The re-
sponse elements of NF-jB are localized in the proximal promoterregions of cell adhesion molecule genes, including those of ICAM-
1 and VCAM-1 [11]. Therefore, to explore whether IL-33-mediated
ICAM-1/VCAM-1 promoter activity is dependent on the NF-jB
pathway, we examined the effect of IL-33 on the NF-jB response
elements by measuring luciferase activity of a 4x-jB reporter gene.
Knocking down IL-33 attenuated (Supplementary Fig. 1A), and
overexpressing IL-33 potentiated (Supplementary Fig. 1B), the
luciferase activity of the 4x-jB reporter gene in HUVECs.
NF-jB is an inducible factor that responds to inﬂammatory
mediators. The NF-jB pathway is regulated by several mechanisms
in both the cytoplasm and the nucleus, such as nuclear transloca-
tion, DNA binding activity, post-translational modiﬁcation, and
310 Y.-S. Choi et al. / Biochemical and Biophysical Research Communications 421 (2012) 305–311proteasomal degradation [17]. Therefore, to determine the key
steps in the regulation of NF-jB activity, we investigated changes
in the expression of the p65 subunit following IL-33 knockdown
in HUVECs. Interestingly, endogenous p65 expression was signiﬁ-
cantly attenuated in IL-33-silenced HUVECs (Supplementary
Fig. 1C). These results suggest that IL-33 may modulate the NF-
jB pathway to induce ICAM-1 and VCAM-1 expression.3.5. IL-33 upregulates NF-jB p65 expression in endothelial cells
NF-jB p65 levels were reduced following IL-33 knockdown
(Fig. 4A and B) and elevated following IL-33 overexpression
(Fig. 4C and D) as determined by qRT-PCR and Western blot anal-
yses. These ﬁndings indicated that IL-33 upregulates NF-jB p65
expression to potentiate the expression of cell adhesion molecules,
such as ICAM-1 and VCAM-1.
To determine whether IL-33 transcriptionally regulates p65, we
performed a p65 promoter reporter assay. The promoter activity of
p65 was downregulated by IL-33 siRNA treatment (Fig. 4E) and
dose-dependently upregulated by IL-33 overexpression in HUVECs
(Fig. 4F). To identify more speciﬁcally the region of the p65 pro-
moter that is responsible for the IL-33 effect, we constructed sev-
eral mutant forms of the p65 promoter. The region between
600 and 900 bp is important for IL-33-mediated induction of
p65 (Fig. 4G). Therefore, we performed a ChIP assay to determine
whether IL-33 interacts with the p65 promoter. DNA was ampliﬁed
with primers spanning from 900 to 600 bp of the p65 promoter,
but no PCR products were produced with primers corresponding to
the 30 region of the p65 locus (Fig. 4H), suggesting that nuclear IL-
33 most likely induces p65 transcription by binding to the p65 pro-
moter. Overexpression of IL-33 in p65-depleted HUVECs did not in-
crease ICAM-1/VCAM-1 mRNA levels as measured by RT-PCR
(Fig. 4I). Overall, IL-33 acts as a p65 transcriptional regulator to
control ICAM-1/VCAM-1 expression.4. Discussion
Here, we describe the role of IL-33 as a nuclear factor in regulat-
ing tissue inﬂammatory properties. Nuclear IL-33 increases NF-jB
p65 mRNA expression by binding to the NF-jB p65 promoter in
endothelial cells. This leads to the expression of ICAM-1 and
VCAM-1 that increase monocyte adhesion in basal and TNF-a-
stimulated conditions.
Under normal conditions, IL-33 is expressed in the nucleus of
HEV endothelial cells [4] that have morphologies distinct from
those cells of normal vessels and express speciﬁc cell adhesion
molecules (ICAM, VCAM) that promote the recruitment of lympho-
cytes [18]. IL-33 and cell adhesion molecules are also found in the
vessel of inﬂammatory diseases, such as atherosclerosis and rheu-
matoid arthritis [9,19]. Thus, we expected a relationship between
the expression of IL-33 and that of cell adhesion molecules. Inter-
estingly, we found that knockdown or ectopic expression of IL-33
in endothelial cells regulated ICAM-1 and VCAM-1 expression. In
addition, TNF-a-activated endothelial cells showed IL-33-depen-
dent ICAM-1 and VCAM-1 induction and enhanced monocyte
adherence. According to numerous reports, IL-33 functions as a
cytokine released from damaged cells under necrotic conditions
rather than secreted normally through a ER-Golgi-dependent path-
way [6]. The released IL-33 binds to ST2 receptor and is involved in
activating inﬂammatory reactions. For example, IL-33, as a cyto-
kine, induces the expression of ICAM-1, VCAM-1, E-selectin, and
MCP-1 through the NF-jB pathway in human carotid atheroscle-
rotic plaques [14]. Contrary to this, our data revealed that ectopic
IL-33 expression increased ICAM-1 and VCAM-1 expression evenafter ST2 had been silenced by siRNA treatment, implying IL-33
as an intracellular factor under these conditions, not as a cytokine.
Previous reports suggested that nuclear IL-33 has properties of
transcription repressor and the N-terminal region of the IL-33 pro-
tein has a chromatin binding motif (CBM) structure, resembling
the chromatin binding motif in Kaposi sarcoma herpesvirus (KSHV)
LANA (latency-associated nuclear antigen). LANA and IL-33 attach
to heterochromatin and mitotic chromatin through the CBM [10].
Because KSHV LANA attenuates p53 promoter activity and pro-
motes CDK2 promoter activity [20], IL-33 may also directly bind
to target chromatin via its N-terminal chromatin binding motif
or through a protein–protein interaction with other transcription
factors through its C-terminal region. Accordingly, depending on
the gene and cell type-speciﬁc promoters, IL-33 could act as a tran-
scriptional activator or repressor.
Because the NF-jB transcription factor binding site is highly
conserved in the promoter regions of ICAM-1 and VCAM-1, we
hypothesized that IL-33 acts as a nuclear regulator of the NF-jB
pathway, [11]. In support of this idea, IL-33 shares very similar bio-
logical characteristics with IL-1a and HMGB1 that possess dual
functions as cytokines and nuclear factors. Full-length IL-1a in
the absence of IL-1 receptor binding activates luciferase activity
of NF-jB and AP1 and expression of the NF-jB-dependent cyto-
kines IL-6 and IL-8 [21]. HMGB1 also enhances the DNA binding
efﬁciency of p65/p50 to increases expression of the NF-jB target
gene, VCAM-1 [22]. As with those factors, IL-33 as a nuclear factor
may be involved in the modulation of the NF-jB pathway. NF-jB/
Rel family (RelA, RelB, c-Rel, p100/p52, and p105/p50) are constitu-
tively expressed in endothelial cells [23]. Their expression is auto-
regulated by the NF-jB pathway, except for p65 (RelA) as the
promoter region of p65 contains no NF-jB response element
[24]. Currently, transcriptional regulation of p65 has not been well
studied. The Sp1 transcription factor is solely known as a regulator
of p65 expression. For instance, MDM2 directly binds to the Sp1
site which is in the proximal region of the p65 coding sequence
to induce p65 transcription [25]. In addition, human cytomegalovi-
rus infection leads to induction of Sp1 both at the mRNA and pro-
tein levels and Sp1 protein induces p65 transcription [26].
However, nuclear IL-33 was unlikely to affect mRNA expression
(data not shown). We found that IL-33 markedly upregulated
p65 mRNA, we further examined p65 promoter activity and IL-33
promoter binding. We concluded that IL-33 binds to the p65 pro-
moter to ultimately upregulate cell adhesion molecules in endo-
thelial cells, even though it remains to be determined whether
IL-33 is a transcription factor or a cofactor.
Overall, the data suggest that endogenous IL-33 as a nuclear fac-
tor regulates not only basal levels of cell adhesion molecules in
normal endothelial cells, but also promotes cell adhesion molecule
expression to recruit leukocytes in cytokine-exposed endothelial
cells. We provide evidence that nuclear IL-33 upregulates NF-jB
p65 mRNA and subsequently promotes the expression of cell adhe-
sion molecules. Therefore, we demonstrate that nuclear IL-33 is
likely to contribute to endothelial cell activation and is required
for maintaining endothelial homeostasis through regulating the
inﬂammatory response.
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